NF Network partnership with SpringWorks Therapeutics

Author: NF Network
Published On: 06/03/2019

The NF Network is pleased to announce its partnership with SpringWorks Therapeutics. They are a clinical-stage biopharmaceutical company that has chosen Neurofibromatosis as one of the rare diseases they focus their research on. They just announced that the Food and Drug Administration (FDA) granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of patients with neurofibromatosis type 1-associated inoperable plexiform neurofibromas that are progressing or causing significant morbidity.  SpringWorks expects to initiate a phase 2b clinical trial for pediatric and adult patients in the third quarter of 2019.  

Springworks’ press release is excerpted here.   


Please contact the NF Network with any questions at:

Want to view archived newsletters? Click Here!


Sign up to receive the latest neurofibromatosis news and information in your inbox!



Have a story you'd like to share with the NF community? Click Here!